Recombinant Rhesus monkey ARHGAP19 Protein, His-tagged

• Cat.No.: ARHGAP19-390R
• Product Overview: Recombinant Rhesus monkey ARHGAP19 full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Rhesus monkey
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: ARHGAP19 Rho GTPase activating protein 19 [ Macaca mulatta (Rhesus monkey) ]
• Official Symbol: ARHGAP19
• Synonyms: ARHGAP19; rho GTPase-activating protein 19
• Gene ID: 705496
• mRNA Refseq: NM_001266583
• Protein Refseq: NP_001253512
• UniProt ID: H9G104

Reviews

11/27/2022

This specificity enables precise quantification and characterization of ARHGAP19 and its interactions with other molecules or proteins of interest.

11/15/2021

Its resistance to degradation and denaturation allows for longer storage times and repeated use without compromising its performance or functionality.

08/05/2021

Their prompt and insightful responses to inquiries and troubleshooting requests enable me to tackle experimental obstacles with confidence and efficiency.

05/28/2021

They understand that each research project may have unique requirements, and they are more than willing to address these specific needs.

07/13/2019

When used in Western blotting experiments, the ARHGAP19 protein produces distinct protein bands, allowing for easy visualization and interpretation.

04/06/2018

ARHGAP19 protein is known for its stability and robustness, making it suitable for a wide range of experimental conditions.

08/09/2017

The manufacturer's commitment to providing excellent technical support is truly impressive.

06/25/2016

Their proactive approach ensures that I am always working with the latest advancements in ARHGAP19 protein research, allowing me to explore new avenues and potentially uncover groundbreaking discoveries.

Q&As

Does ARHGAP19 have any known alternative splice variants?

As of now, there are no known alternative splice variants of ARHGAP19 documented in scientific literature or databases. However, alternate splicing events can give rise to different isoforms with potentially distinct functions in various tissues or developmental stages. Further investigations are required to determine if ARHGAP19 undergoes alternative splicing.

Are there any known interactions or binding partners of ARHGAP19?

While specific binding partners of ARHGAP19 have not been extensively studied, it is known to interact with RhoA and regulate its activity. ARHGAP19 may also interact with other proteins involved in Rho GTPase signaling pathways, although further research is needed to identify specific binding partners.

Can ARHGAP19 be regulated by any external factors?

The regulation of ARHGAP19 expression or activity by external factors is currently not well known. However, it is possible that various signaling pathways or stimuli, such as growth factors or extracellular matrix components, may influence ARHGAP19 expression or function. Understanding the regulatory mechanisms that affect ARHGAP19 could provide insights into its role in cellular processes.

Can dysregulation of ARHGAP19 lead to pathological conditions?

While the specific pathological conditions associated with ARHGAP19 dysregulation are not well defined, alterations in Rho GTPase signaling, which ARHGAP19 modulates, have been implicated in multiple diseases. Dysregulation of RhoA activity, due to abnormal ARHGAP19 function or expression, could potentially contribute to pathological conditions such as cancer, cardiovascular disorders, or neurological disorders. However, extensive investigation is needed to establish a direct link between ARHGAP19 dysregulation and disease pathogenesis.

Are there any known post-translational modifications of ARHGAP19?

At present, there is limited information on post-translational modifications of ARHGAP19. However, many Rho GAP proteins can undergo phosphorylation or ubiquitination, which can affect their activity or stability. Determining if ARHGAP19 undergoes any post-translational modifications could provide further insights into its regulation and function.

Is ARHGAP19 associated with any diseases?

Currently, there is limited information on specific diseases associated with ARHGAP19. However, alterations in Rho GTPase signaling pathways, which ARHGAP19 is involved in, have been implicated in various diseases such as cancer, cardiovascular disorders, and neurological conditions. Further research is needed to explore if ARHGAP19 has a direct role in disease development or progression.

Is ARHGAP19 conserved across different species?

ARHGAP19 shows conservation across various species, including mammals, birds, and reptiles. Its high level of conservation suggests that it plays an important role in fundamental cellular processes. Studying ARHGAP19 in different species can provide valuable insights into its evolutionary significance and functional conservation.

Does ARHGAP19 interact with any other proteins?

The protein interaction partners of ARHGAP19 have not been extensively characterized. However, as a Rho GTPase-activating protein (Rho GAP), ARHGAP19 is expected to interact with Rho family GTPases, such as RhoA, RhoB, or RhoC, and modulate their activity. Additionally, ARHGAP19 may interact with other signaling proteins or cytoskeletal components to regulate cellular processes. Identifying and characterizing the protein interaction network of ARHGAP19 would provide valuable insights into its functional roles.

Has ARHGAP19 been implicated in cancer or metastasis?

There is limited information regarding the involvement of ARHGAP19 in cancer or metastasis. However, since Rho GTPase signaling, regulated by ARHGAP19, can influence cancer cell migration and invasion, further investigation is necessary to determine if ARHGAP19 has a role in cancer progression or metastasis.

Is ARHGAP19 a tumor suppressor protein?

The role of ARHGAP19 as a tumor suppressor protein is currently unclear as there is limited information available. While dysregulated Rho GTPase signaling has been implicated in cancer progression, no direct evidence linking ARHGAP19 to tumor suppression or its involvement in cancer has been reported to date. Further studies are needed to determine if ARHGAP19 functions as a tumor suppressor or if it plays a role in cancer development or progression.

Are there any genetic variants or mutations in ARHGAP19 associated with diseases?

Currently, there is limited information on genetic variants or mutations specifically associated with ARHGAP19 and diseases. However, considering the importance of Rho GTPase signaling in various diseases, it would be interesting to explore if alterations in ARHGAP19 function or expression contribute to disease susceptibility or progression. Further research is needed in this area.

Is ARHGAP19 implicated in any diseases or disorders?

Currently, there is limited information about the involvement of ARHGAP19 in specific diseases or disorders. However, dysregulation of Rho GTPase signaling, which ARHGAP19 participates in, has been linked to various pathological conditions. ARHGAP19 dysregulation or mutations could potentially contribute to diseases such as cancer, cardiovascular disorders, or neurological disorders. Further research is needed to establish the precise role of ARHGAP19 in disease pathogenesis.

Is ARHGAP19 involved in any developmental processes?

While the exact role of ARHGAP19 in development is not well understood, its expression in developing embryos suggests a potential involvement in early developmental processes. Further research is needed to determine the specific contributions of ARHGAP19 in embryogenesis or organogenesis.